Download Using Large Observational Data to Inform Pediatric Drug Safety

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Using Large Observational
Data to Inform
Pediatric Drug Safety
James Feinstein, MD MPH
Outline
• A few case examples:
1. Evaluation of existing policy
2. Evidence to inform clinical practice
3. Evidence to shape new policy
• Illustrate ways to present data to stakeholders
The problem…
The problem…
• Just like adults, kids experience side effects,
drug-drug interactions, and adverse drug
events, too!
• We lack high-quality, pediatric-specific
evidence for many medications
• We have limited mechanisms to
monitor/reduce harm
Why use big data for drug safety research?
• Pediatric population exposed to these drugs is
small (compared to adult population)
• Side effects, drug-drug interactions, adverse
drug events are rare
• Necessary to ensure sample size requisite to
make valid conclusions
1. Evaluation of Existing Policy
1. Evaluation of Existing Policy
• In 2007, the FDA implemented Tall Man
lettering
– Improve safety for look-alike or sound-alike drugs
– cloNIDine and clonazePAM
• No small task to implement
– Impacts FDA labeling, drug compendiums,
electronic medical records
• But, does it do anything to reduce error?
Methods
• Pharmacy data for pediatric inpatients (<21 years old) from
42 children’s hospitals in 2004–2012
• Pre-specified set of 8 potential LA-SA drug error patterns
• Searched within each hospitalization for the occurrence of
one of these patterns for a total of 12 LA-SA drug pairs
• Assessed for potential change in error rates before and
after Tall Man lettering implementation using segmented
regression analyses for each drug pair
Results
• 1,676,700 hospitalizations
• No statistically significant change was detected
for either the intercept or the slope of LA-SA
error rate for each of the drug pairs
• No downward trend in potential LA-SA drug error
rates was evident over any time period 2004
onwards
Trends of potential look-alike sound-alike errors before and after Tall Man lettering
implementation.
Wenjun Zhong et al. BMJ Qual Saf 2016;25:233-240
Copyright © BMJ Publishing Group Ltd and the Health Foundation. All rights reserved.
2. Evidence to Inform Clinical Practice
2. Evidence to Inform Clinical Practice
• Polypharmacy increases the potential for drug
interactions
• Direct implications for prescribers,
pharmacists, and healthcare systems
• We aimed to assess the:
– Prevalence of PDDI exposures
– Specific problematic drug combinations
Methods
• PHIS data from 2011 for patients <21 yo
• For each patient day, we analyzed every
potential 2-way drug-drug interaction
– MicroMedex DRUG REAX compendium
– Severity (contraindicated, major, moderate)
– Evidence (excellent, good, fair)
– Mechanism of harm
Results
498,956 Hospitalizations  4,497,448 PDDI Exposures
Results
MAJOR DRUG DRUG INTERACTIONS
Drug Pair
Type of Interaction
Prevalence 95% CI
Fentanyl and Morphine
Additive respiratory
depression
13.17
(13.07,
13.27)
Fentanyl and Midazolam
Additive respiratory
depression
11.19
(11.09,
11.28)
Midazolam and Morphine
Additive respiratory
depression
9.20
(9.11,
9.28)
Results
A large proportion of contraindicated and major
interactions were due to less common PDDIs
Fentanyl and Morphine
2.8%
3. Evidence to Shape New Policy
3. Evidence to Shape New Policy
• Medicare pays for Medication Therapy
Management in the adult population,
supervised by a pharmacist
• We have no similar mechanism to periodically
review medications for complex children
• How would we identify patients requiring
focused pharmacy reviews?
Methods
• Colorado Medicaid medication claims
– 242,230 children <21 yo
– 1 year continuous enrollment
• We calculated the:
– Daily maximum count over 1 year
– The durations for each level
– Patient characteristics associated with high-degree, highduration polypharmacy
• Multinomial logistic regression to identify patient
characteristics associated with high-depth high-duration
Hotspotting High Risk Patients
Who are the high-degree subjects?
High-degree polypharmacy was associated with
increasing age, male gender, and presence of a CCC
Stay tuned…
• We have a forthcoming position piece that
“prescribes” the use of big population-level
data to:
– Investigate 5 major domains of drug safety
– Prioritize pediatric drug research and funding
Questions? Ideas?
• Thank you!
The Team
Allison Kempe, MD MPH
Chris Feudtner, MD PhD MPH
Robert Valuck, PhD RPH
Dingwei Dai, PhD
Wenjun Zhong, PhD
UC Denver/CHCO
UPenn/CHOP
UC Denver/SOP
UPenn/CHOP
UPenn/CHOP